New Research Finds Vitamin C Could Aid Treatment for Acute Myeloid Leukemia

636081520091215764food supplementscrop.jpg

30 Aug 2016 --- New findings have shown that by supplementing an epigenetic cancer drug called decitabine with vitamin C, it enhanced the drug's ability to impede cancer cell growth and trigger cellular self-destruction in cancer cell lines, prompting the start of a dedicated pilot study.

The pilot clinical trial involving adult patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) at Rigshospitalet in Copenhagen, Denmark, will combine a drug called azacitidine, the standard of care therapy, with vitamin C. 

Many cancer patients are deficient in vitamin C; the proposed approach seeks to correct this deficiency rather than overload patients with the vitamin.

"If the pilot trial is successful, we plan to pursue a larger trial to explore this strategy's potential as a straightforward and cost-effective way to improve the existing therapy for AML and MDS," said Peter Jones, Ph.D., D.Sc., co-senior author of the PNAS study, chief scientific officer at Van Andel Research Institute (VARI) and co-leader of the Van Andel Research Institute-Stand Up To Cancer (VARI-SU2C) Epigenetics Dream Team. 

However, the authors of the study urge patience and caution. Kirsten Grønbæk, M.D., DMSc., chief hematologist and professor at University of Copenhagen’s Rigshospitalet and member of the VARI-SU2C Epigenetics Dream Team, told NutritionInsight: “We will only know if the results of this study will impact actual cancer treatment after a large randomized clinical trial that will run from next year if the pilot data comes out positively. Generally 90 percent of aza patients will have responded after 6 months. Thus I would say we would know whether or not this impacts treatment of MDS/AML within the next 2-3 years.”

The proposed strategy reflects a continuing move toward combination therapies, particularly when it comes to epigenetic approaches, which target the mechanisms that control whether genes are switched "on" or "off."

"This type of combination therapy is promising but more work is needed to determine its safety and efficacy," Grønbæk said. "It is truly exciting to consider that there could be a simple and elegant approach to help patients fight MDS and AML. However, as a physician, I strongly urge patients to wait for the results of the clinical trial and to discuss all dietary and supplemental changes with their doctors."

There are hopes that this study could prompt research into how vitamin C could improve treatments for other types of cancer, too. 

“We investigated cell lines from various cancers and observed similar effects,” explained Grønbæk, “However, hypomethylating drugs are only used in clinical trials in solid tumors. It would be relevant to also investigate the effects of vitamin C supplement in these trials. However, only controlled clinical trials can answer that question.”

For now, the clinical study will look at adult patients with MDS or AML. “We are currently running a pilot trial of 20 patients,” said Grønbæk, “If this comes out positively, we will run a large clinical trial with participating hospitals from US and Nordic countries.”
 
by Hannah Gardiner

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Health & Nutrition News

Resistant starch for athletic performance: Australian start-up launches gut hydration system

21 Nov 2018 --- Australia-based Flinders University start-up, Preserve Health, has launched a two-step hydration system backed by more than 20 years of medical research between Flinders and Yale Universities. The system, called PREPD, uses a unique resistant starch that has been identified as a key factor in promoting hydration in the gut.

Health & Nutrition News

The next infant formula staple? NZMP eyes milk fat globule membrane potential

21 Nov 2018 --- As scientific understanding of infant development evolves, the industry is seeing growing opportunities for infant nutrition formulas that come as close to human breast milk as possible, and which benefit aspects such as brain and immune health. In this space, NZMP, Fonterra’s B2B ingredients business, is making strides in uncovering the potential of milk fat globule membrane (MFGM).

Health & Nutrition News

“Breakthrough” treatment seeks to protect people with peanut allergies through exposure to peanut protein

20 Nov 2018 --- Medical researchers have developed a new treatment for protection against accidental exposure to peanut. Although the treatment is not a “quick fix,” the researchers note their study results show it is possible for some people with peanut allergy to protect themselves from accidental ingestion by building up their tolerance to peanut over time.

Regulatory News

Oleic acid CHD claims success: US FDA approves qualified claim petition on high level foods 

20 Nov 2018 --- The US Food and Drug Administration (FDA) has responded positively to a petition for a new qualified health claim for edible oils containing oleic acid. As a result, products with an oleic acid content upward of 70 percent, such as certain olive, canola and sunflower oils, can be labeled as carrying cardiovascular benefits, but only when replacing heart-damaging saturated fat.

Health & Nutrition News

Gluten-free diet health benefits actually down to change in dietary fiber sources, study finds

19 Nov 2018 --- Following a gluten-free diet can lead to a reduction of intestinal discomfort, such as bloating, but this may be due to a change in dietary fiber composition, suggest Danish researchers. The University of Copenhagen study notes that the healthy, gluten-free diets in their study required a shift of fiber sources from wheat and rye to vegetables, brown rice, corn, oat and quinoa, and that certain health improvements were down to these sources – not the absence of gluten. 

More Articles
URL : http://www.nutritioninsight.com:80/news/new-research-finds-vitamin-c-could-aid-treatment-for-acute-myeloid-leukemia.html